Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer

Mathur, S; Mincher, D; Turnbull, A; Stevens, C; Poole, A

doi:10.1016/s0959-8049(16)61501-0

All Outputs (2)

Development of mitochondria- and protease-specific prodrugs in the potential treatment of parasitic helminth infections (2016)
Presentation / Conference
Oluwadare, E., Rehan, A., Ding, Y., Turnbull, A., Malone, E., Mincher, D., & Proudfoot, L. (2016, September). Development of mitochondria- and protease-specific prodrugs in the potential treatment of parasitic helminth infections. Poster presented at Molecular & Cellular Biology of Helminth Parasites X, Hydra, Greece

Anthelmintic resistance and the shortage of new drugs represent an urgent need for the development of novel anti-parasite drugs with effective delivery to the target site. Reduced bioavailability and sub-optimal doses can be responsible for generatio... Read More about Development of mitochondria- and protease-specific prodrugs in the potential treatment of parasitic helminth infections.

Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer (2016)
Journal Article
Mathur, S., Mincher, D., Turnbull, A., Stevens, C., & Poole, A. (2016). Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer. European Journal of Cancer, 61, S142. https://doi.org/10.1016/s0959-8049%2816%2961501-0

Background: In spite of major advances in the diagnosis and treatment of cancer, there remains a paucity of biomarkers for early detection. Legumain is a potential cancer biomarker and a molecular target for imaging and drug targeting. Legumain is a... Read More about Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer.